AVGO

51.2% implied revenue CAGR

Today's P/S implies ~51.2% revenue CAGR for five years, but realized growth is unavailable.

0%–0%

WATCH sizing fits a high-quality business where the current price remains close to or above conservative fair value and the next catalyst must confirm AI upside.

Strongest bear case

The forward P/E of 23.24 that makes AVGO look reasonable is an illusion: it is price ($380.91) divided by an implied forward EPS of ~$16.39, a ~170% jump from TTM EPS of $6.0071. On realized numbers the stock is 63x trailing earnings, 53.2x EV/EBITDA, and 24.5x EV/revenue — historically extreme (EV/EBITDA was 14.4x in FY2022). The entire return is multiple re-rating, not delivered fundamentals. Yet the one packet catalyst shows the $100B+ 2027 target was reiterated, not raised, which triggered the drop from the $495 high (now -23%). Custom-ASIC revenue is structurally tied to a handful of hyperscalers who are the very parties capable of in-sourcing or multi-sourcing (packet cites MRVL as a networking rival). Multiple insiders sold in July into that reiteration. If forward EPS is even modestly optimistic, the 'cheap' forward multiple evaporates.

Missed / under-weighted red flags

• Customer concentration is 'unavailable' but structurally extreme for custom ASICs — a peer like NVDA/MU would carry an itemized concentration risk; here it hides in prose.
• No geopolitical/China export-control risk itemized at all, despite semiconductor peers (NVDA, MU) carrying that tail; symmetric treatment requires AVGO's analogue.
• Trailing-vs-forward P/E gap (63x → 23x) prices ~170% EPS growth — the single biggest embedded assumption is under-weighted.
• EV exceeds market cap by ~$28B net debt (total debt/equity 0.80); net-debt/EBITDA left 'unavailable' rather than computed (EBITDA TTM ~$34B implies ~0.8x).
• Momentum rolling over: 1-year return decelerated 41%→32%, -23% from high, analyst mix shifted toward more holds — a de-rating already underway.
• Multiple officers (Brazeal -50k shares, Delly, Page) sold in July at $373-401 right after the reiteration disappointment.

Fair-value critique

The $360 base is not an independent valuation: it plugs the market-implied forward EPS of ~$16.39 (itself derived as price ÷ the packet's 23.24 forward P/E) back into a 22x multiple, yielding a number 5% below spot by construction. This is circular — it re-prices consensus, not intrinsic value. It embeds ~170% EPS growth off TTM $6.0071 with zero bottoms-up support, and the only forward data point (reiterated, not raised, $100B+ 2027 target) argues consensus may be topping out. If forward EPS is 20% high, a 22x anchor implies ~$290, below the stated $300 low. The high case at 430 simply assumes multiple persistence.